Product Description
HEC 68498 is an oral inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin in clinical development at HEC Pharm for the treatment of idiopathic pulmonary fibrosis.
Mechanisms of Action: PI3K Inhibitor,MTOR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sunshine Lake Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Idiopathic Pulmonary Fibrosis|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HEC68498-P-01 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2021-02-26 |
34% |
| PCD-DHEC68498-17-001 | P1 |
Completed |
Idiopathic Pulmonary Fibrosis |
2019-03-15 |
53% |